Name: Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Uploaded: 2023-08-18T14:10:00
Description: Watch this Scientific Journal Video about Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models at JoVE.com

The authors wish to acknowledge funding from the National Institutes of Health (R01AI155922). Microscopy was performed at the Chapel Hill Analytical and Nanofabrication Laboratory (CHANL), a member of the North Carolina Research Triangle Nanotechnology Network, RTNN, which is supported by the National Science Foundation, Grant ECCS-1542015, as part of the National Nanotechnology Coordinated Infrastructure, NNCI.

All animal experiments were conducted in accordance with the Animal Welfare Act and the Public Health Service Policy on Humane Care and Use of Laboratory Animals. The study protocol was approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center. Healthy female BALB/c mice, ~6-8 weeks old, were administered the dry powder content of one dosator by intrapulmonary aerosol delivery for a pharmacokinetic study using spectinamide 1599 dry powders9. T...

Customizable Disposable Dosators to Deliver Dry Powder Aerosol Drugs to Mice

<ol>
	<li>Wu, X., Li, X., Mansour, H. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Surface+analytical+techniques+in+solid-state+particle+characterization+for+predicting+performance+in+dry+powder+inhalers.">Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers.</a> KONA Powder and Particle Journal. 28, 3-18 (2010).</li><li>Maloney, S. E., Mecham, J. B., Hickey, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Performance+testing+for+dry+powder+inhaler+products:+towards+clinical+relevance.">Performance testing for dry powder inhaler products: towards clinical relevance.</a> KONA Powder and Particle Journal. 40, 172-185 (2023).</li><li>Maloney, S. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Spray+dried+tigecycline+dry+powder+aerosols+for+the+treatment+of+nontuberculous+mycobacterial+pulmonary+infections.">Spray dried tigecycline dry powder aerosols for the treatment of nontuberculous mycobacterial pulmonary infections.</a> Tuberculosis. 139, 102306 (2023).</li><li>Kaur, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+hand-held+apparatus+for+&amp;#34;nose-only&amp;#34;+exposure+of+mice+to+inhalable+microparticles+as+a+dry+powder+inhalation+targeting+lung+and+airway+macrophages.">A hand-held apparatus for &amp;#34;nose-only&amp;#34; exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages.</a> European Journal of Pharmaceutical Sciences. 34 (1), 56-65 (2008).</li><li>Yi, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Whole-body+nanoparticle+aerosol+inhalation+exposures.">Whole-body nanoparticle aerosol inhalation exposures.</a> Journal of Visualized Experiments. (75), e50263 (2013).</li><li>Chung, Y. H., Han, J. H., Lee, Y. -. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+study+on+subchronic+inhalation+toxicology+of+1-chloropropane.">A study on subchronic inhalation toxicology of 1-chloropropane.</a> Toxicological Research. 31 (4), 393-402 (2015).</li><li>Kuehl, P. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Regional+particle+size+dependent+deposition+of+inhaled+aerosols+in+rats+and+mice.">Regional particle size dependent deposition of inhaled aerosols in rats and mice.</a> Inhalation Toxicology. 24 (1), 27-35 (2012).</li><li>Manser, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Design+considerations+for+intratracheal+delivery+devices+to+achieve+proof-of-concept+dry+powder+biopharmaceutical+delivery+in+mice.">Design considerations for intratracheal delivery devices to achieve proof-of-concept dry powder biopharmaceutical delivery in mice.</a> Pharmaceutical Research. 40, 1165-1176 (2023).</li><li>Stewart, I. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+and+characterization+of+a+dry+powder+formulation+for+anti-tuberculosis+drug+spectinamide+1599.">Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599.</a> Pharmaceutical Research. 36 (9), 136 (2019).</li><li>Durham, P. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disposable+dosators+for+pulmonary+insufflation+of+therapeutic+agents+to+small+animals.">Disposable dosators for pulmonary insufflation of therapeutic agents to small animals.</a> Journal of Visualized Experiments. (121), e55356 (2017).</li><li>Miwata, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratracheal+administration+of+siRNA+dry+powder+targeting+vascular+endothelial+growth+factor+inhibits+lung+tumor+growth+in+mice.">Intratracheal administration of siRNA dry powder targeting vascular endothelial growth factor inhibits lung tumor growth in mice.</a> Molecular Therapy: Nucleic Acids. 12, 698-706 (2018).</li><li>Duret, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pharmacokinetic+evaulation+in+mice+of+amorphous+itraconazole-based+dry+powder+formulations+for+inhalation+with+high+bioavailability+and+extended+lung+retention.">Pharmacokinetic evaulation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.</a> European Journal of Pharmaceutics and Biopharmaceutics. 86 (1), 46-54 (2014).</li><li>Maloney, S. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Preparation+strategies+of+the+anti-mycobacterial+drug+bedaquiline+for+intrapulmonary+routes+of+administration.">Preparation strategies of the anti-mycobacterial drug bedaquiline for intrapulmonary routes of administration.</a> Pharmaceuticals. 16 (5), 729 (2023).</li><li>Price, D. N., Kunda, N. K., Muttil, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Challenges+associated+with+the+pulmonary+delivery+of+therapeutic+dry+powders+for+preclinical+testing.">Challenges associated with the pulmonary delivery of therapeutic dry powders for preclinical testing.</a> KONA Powder and Particle Journal. 36, 129-144 (2019).</li><li>Qiu, Y., Liao, Q., Chow, M. Y. T., Lam, J. K. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratracheal+administration+of+dry+powder+formulation+in+mice.">Intratracheal administration of dry powder formulation in mice.</a> Journal of Visualized Experiments. (161), e61469 (2020).</li><li>Fiegel, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Preparation+and+in+vivo+evaluation+of+a+dry+powder+for+inhalation+of+capreomycin.">Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.</a> Pharmaceutical Research. 25 (4), 805-811 (2008).</li></ol>

As mice are obligate nose breathers, delivery via passive inhalation for initial proof-of-concept studies makes efficiency and dose estimation challenging as the powder must pass the nose and throat in a manner dependent on particle properties and powder dispersion efficiency7,8,14. The use of the dosators developed herein bypasses the nose and throat, with the dosator inserted to the first bronchial bifurcation<sup cla...

The use of dry powder inhalers (DPIs) for pulmonary drug delivery has garnered significant interest over the past three decades due to the global phase-out of chlorofluorocarbon propellants1,2. DPIs offer numerous benefits over other pulmonary delivery systems, such as metered dose inhalers and nebulizers, including formulation stability, portability, ease of use, and propellant-free dispersal mechanisms2. However, before moving DPI products toward clinical translation, several preclinical studies must be conducted, many of which are initially completed using a murine model. Nevertheless, technologies available to deliver dry powders accurately and reproducibly to small animals are limited.
Common methods to deliver dry powders to small animals, such as mice, include passive inhalation3,4,5,6,7 and direct administration8,9,10,11,12,13. Passive inhalation typically requires a custom chamber that utilizes large doses of spray-dried powder to prepare a sufficient aerosol cloud. As mice are obligate nose breathers14, delivery by passive inhalation requires the powder to travel through the nose and throat to reach the lungs, necessitating the maintenance of an aerosol cloud with sufficient particle aerodynamic properties7,8. While a useful technique that is more physiologically relevant than direct delivery due to inhalation as a result of normal breathing14, it may not be suitable for initial studies where powder mass is limited.
Alternatively, a number of intratracheal delivery devices for direct dry powder delivery have been reported8,9,10,11,12,13. Intratracheal devices bypass the nose and throat, delivering the powder directly to the lungs and allowing for finer control over the delivered dose14. Additionally, some devices, especially those prepared using a tamping loading procedure9, can be prepared with smaller quantities, which is an important consideration for initial proof-of-concept studies. The lack of universally available intratracheal delivery devices has hindered their potential for use, limiting availability and leading to interlaboratory differences14. In this study, we propose a simple, inexpensive, disposable dosator for intratracheal delivery that can be utilized for proof-of-concept murine studies in the development of dry powder aerosols.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>0.6 mL microcentrifuge tubes</td>
			<td>Fisher Scientific</td>
			<td>05-408-120</td>
			<td></td>
		</tr>
		<tr>
			<td>Analytical balance</td>
			<td>Mettler Toledo</td>
			<td>AR1140</td>
			<td>Any analytical balance with sufficient range can be used</td>
		</tr>
		<tr>
			<td>Blunt stainless-steel needle, 1 inch, 21 G</td>
			<td>McMaster-Carr</td>
			<td>75165A681</td>
			<td></td>
		</tr>
		<tr>
			<td>Blunt stainless-steel needle, 1 inch, 22 G</td>
			<td>McMaster-Carr</td>
			<td>75165A683</td>
			<td></td>
		</tr>
		<tr>
			<td>Blunt stainless-steel needle, 1 inch, 25 G</td>
			<td>McMaster-Carr</td>
			<td>75165A687</td>
			<td></td>
		</tr>
		<tr>
			<td>Disposable syringe with luer lock (1 mL)</td>
			<td>Fisher Scientific</td>
			<td>14-823-30</td>
			<td>3-mL syringes can also be used</td>
		</tr>
		<tr>
			<td>Female BALB/c mice&#160;</td>
			<td>Charles River, Wilmington, MA, USA</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>High-performance cascade impactor&#160;</td>
			<td>Next Generation Impactor</td>
			<td>Apparatus 5</td>
			<td></td>
		</tr>
		<tr>
			<td>Lab film (e.g., Parafilm)</td>
			<td>Fisher Scientific</td>
			<td>S37440</td>
			<td></td>
		</tr>
		<tr>
			<td>Low-lint wiper (e.g., Kimwipes)</td>
			<td>Kimberly-Clark Professional</td>
			<td>34133</td>
			<td></td>
		</tr>
		<tr>
			<td>Low-resistance dry powder inhaler&#160;</td>
			<td>RS01 mod 7</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Polypropylene needle, 1.5 inch, 16 G</td>
			<td>McMaster-Carr</td>
			<td>6934A111</td>
			<td></td>
		</tr>
		<tr>
			<td>Polypropylene needle, 1.5 inch, 18 G</td>
			<td>McMaster-Carr</td>
			<td>6934A53</td>
			<td></td>
		</tr>
		<tr>
			<td>Polypropylene needle, 1.5 inch, 20 G</td>
			<td>McMaster-Carr</td>
			<td>6934A55</td>
			<td></td>
		</tr>
		<tr>
			<td>Precision sectioning saw</td>
			<td>TedPella</td>
			<td>812-300</td>
			<td>Belt sander can be used as an alternative</td>
		</tr>
		<tr>
			<td>PTFE needle, 2 inch, 20 G</td>
			<td>McMaster-Carr</td>
			<td>75175A694</td>
			<td></td>
		</tr>
		<tr>
			<td>USP General Chapter &#60;601&#62;&#160;</td>
			<td></td>
			<td></td>
			<td>http://www.uspbpep.com/usp31/v31261/usp31nf26s1_c601.asp</td>
		</tr>
	</tbody>
</table>

disposable dosators intended for dry powder delivery to mice

Dry powder inhalers offer numerous advantages for delivering drugs to the lungs, including stable solid-state drug formulations, device portability, bolus metering and dosing, and a propellant-free dispersal mechanism. To develop pharmaceutical dry powder aerosol products, robust in vivo testing is essential. Typically, initial studies involve using a murine model for preliminary evaluation before conducting formal studies in larger animal species. However, a significant limitation in this approach is the lack of suitable device technology to accurately and reproducibly deliver dry powders to small animals, hindering such models&#39; utility. To address these challenges, disposable syringe dosators were developed specifically for intrapulmonary delivery of dry powders in doses appropriate for mice. These dosators load and deliver a predetermined amount of powder obtained from a uniform bulk density powder bed. This discrete control is achieved by inserting a blunt needle to a fixed depth (tamping) into the powder bed, removing a fixed quantity each time. Notably, this dosing pattern has proven effective for a range of spray-dried powders. In experiments involving four different model spray-dried powders, the dosators demonstrated the ability to achieve doses within the range of 30 to 1100 &#181;g. The achieved dose was influenced by factors such as the number of tamps, the size of the dosator needle, and the specific formulation used. One of the key benefits of these dosators is their ease of manufacturing, making them accessible and cost-effective for delivering dry powders to mice during initial proof-of-concept studies. The disposable nature of the dosators facilitates use in animal procedure rooms, where cleaning and refilling reusable systems and weighing materials is inconvenient. Thus, developing disposable syringe dosators has addressed a significant hurdle in murine dry powder delivery for proof-of-concept studies, enabling researchers to conduct more accurate and reproducible preliminary studies in small animal models for pulmonary drug delivery.

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models 

Disposable Dosators Intended for Dry Powder Delivery to Mice

The aerosol performance&#160;of various spray-dried powders was established prior to use in this study. The aerodynamic particle size distribution (APSD) was described by the mass median aerodynamic diameter (MMAD), representing the size that divides the distribution in two at the 50th percentile (d50), and the geometric standard deviation (GSD), reflecting the breadth of the distribution. The GSD is defined by the square root of the aerodynamic diameter at the 80th percentile divided by ...

Watch this Scientific Journal Video about Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models at JoVE.com

Pharmaceutical dry powder development necessitates reliable in vivo testing, often using a murine model. Device technology for accurately and reproducibly delivering dry powder aerosols to mice is restricted. This study presents disposable dosators for pulmonary drug delivery at mouse-relevant doses, aiding initial proof-of-concept research.

Dry powder inhalers offer numerous advantages for delivering drugs to the lungs, including stable solid-state drug formulations, device portability, bolus ...

We're developing new and existing drugs for inhalational therapy of mycobacterial disease. Our focus is on a novel approach to treat drug-resistant organisms, ensuring safety and efficacy using dry powders. The initial preclinical testing of dry powder inhaler products typically occurs in a murine model prior to movement to a larger animal model.A significant limitation to this approach is the lack of suitable device technology for accurate and reproducible delivery of dry powders to small animals. The disposable dosators that we have developed are easy to manufacture, making them accessible and cost-effective for initial proof-of-concept studies in mice. The disposable nature allows their use in animal procedure rooms without concerns for cleaning, refilling, and weighing out materials for reusable devices.Our future work will employ biotherapeutic moieties targeted to the pathogen that will avoid any effects on the host. This approach then can be tailored to the patient because it's pathogen specific.